[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554812":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":61,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":88,"overallStatus":95,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Matricelab Innove","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"case group",null,"Case group: All the patients who would have benefitted (with informed consent) of a uterine immune profile and a fresh Day-5 SET or a day-5 or-6 SET between January 2020 and march 2024 would be enrolled",{"label":13,"type":10,"description":14,"interventionNames":10},"control group","Pair-matched group: Group without uterine immune profile before the SET Matching criteria will be maternal age (+\u002F-1year) and, number of previous egg retrievals (including the ones without any transfer) and, number of previous ETs and technique used (IVF, ICSI, frozen embryo transfer) and degree of expansion of blastocoel (B1-B2\u002FB3-B4\u002FB5-B6) to reflect the quality of the embryo transferred",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Nathalie Lédée, MD, PhD","CONTACT","33681560394","nathalie.ledee@matricelabinnove.com",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Nathalie LEDEE, MD, PhD","+33681560394","nathalie.ledee@matricelabinnove.fr",[26,48],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Hopital des Bluets- centre d'assistance medicale à la procreation","Paris","Ile de","75012","France","FR",{"type":34,"coordinates":35},"Point",[36,37],2.3488,48.85341,{"lat":37,"lon":36},[40,42,46],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":41},"nathalie-ledee@orange.fr",{"name":43,"role":18,"phone":44,"phoneExt":10,"email":45},"Laura Prat-Ellenberg, MD","+330669580724","laura.prat-ellenberg@bluets.org",{"name":47,"role":18,"phone":10,"phoneExt":10,"email":10},"Nathalie Ledee, MD PHD",{"facility":49,"status":10,"city":28,"state":50,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Hopital des diaconnesse- Centre d'assistance medicale a la procreation","Île-de-France Region",{"type":34,"coordinates":52},[36,37],{"lat":37,"lon":36},[55,59],{"name":56,"role":18,"phone":57,"phoneExt":10,"email":58},"Gwenola KEROMNES, MD","+33662106322","gkeromnes@hopital-dcss.org",{"name":60,"role":18,"phone":10,"phoneExt":10,"email":10},"Gwenola Keromnes, MD",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Dr Nathalie Lédée","MD, PhD","100554812","impact-of-uterine-immune-profiling-and-personalized-treatments-in-patients-receiving-a-single-blastocyst-a-matched-controlled-study-100554812",false,"NCT06503952","Impact of Uterine Immune Profiling and Personalized Treatments in Patients Receiving a Single Blastocyst: a Matched Controlled Study","Impact of Uterine Immune Profiling and Personalized Treatments on Subsequent Live Birth in Patients Receiving a Single Blastocyst: a Matched Controlled Study","UTIMPROSET","For case: Uterine immune profiling followed by a Day-5 fresh SET or day-5 or Day-6 freeze-thawed SET within the nine months following the uterine immune profiling between January 2020 and June 2023.\n\nWill be excluded patients with no SET day-5, with uterine immune profiling more than nine months before, or with no matching pair For control: Blastocyst SET without uterine immune profiling within the year prior the embryo transfer matched to the case group between January 2018 on June 2023\n\n* maternal age (+\u002F-1 year) and\n* the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and\n* the same type of transfer (IVF, ICSI, frozen transfer) and\n* the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).","FEMALE","18 Years","41 Years",{"count":77,"type":78},340,"ESTIMATED","OBSERVATIONAL","A recent randomised controlled trial and previous large cohort studies have shown that the uterine immune environment is a crucial element in improving the performance of Assisted Reproductive therapy (ART). As previous studies mixed Day-3, Day-5, single or doble embryo transfer, the clear influence of the endometrial environment on the embryo itself and its type of transfer (fresh or freeze thawed) need further investigation.\n\nTo complement previous studies, the present matched- pair study aims to select the population who exclusively received a single Day-5 embryo transfer (SET) and benefitted of a uterine immune profiling between 1 January 2020 and 30 June 2023 before the SET Day-5.\n\nThis population will be matched to a population. who did not have uterine immune profiling in the nine months prior to the single Day 5 embryo transfer between 2018 and 2023.\n\nThe matching criteria are the maternal age (+\u002F-1 year), the past history of ART (same number of previous oocytes pick-up, same number of previous embryo transfer) and the same type of transfer (IVF, ICSI, frozen transfer) and the same category of expansion of the blastocoel (B1-B2\u002F B3-B4\u002F B5-B6).\n\nThe primary end-point is the live birth rate (LBR) following the Day 5 SET in the population who benefited from pre-SET immune profiling versus the LBR following the Day 5 SET in the pair- matched population who did not benefit from pre-SET uterine immune profiling Secondary end point are the clinical pregnancy rate and miscarriage rate per SET in the two paired populations",[82,83,84,85,86,87],"Infertility","Success Rate of Assisted Reproductive Therapy","Single Embryo Transfer","Pregnancy Outcomes","Immunological Tolerance","Immune System",[89,90,91,92,93,94],"infertility","success rate of assisted reproductibve therapy","Single embryo transfer","uterine immune profiling","personalized care","Live birth rate","NOT_YET_RECRUITING","2024-12-20",{"date":98,"type":99},"2024-12-27","ACTUAL",{"date":101,"type":78},"2025-01-15",{"date":103,"type":78},"2025-05-30",{"name":5,"class":6},2]